On February 3, 2016, a motion for authority to enter into a transaction which is outside the ordinary course of business was filed in the bankruptcy case of Nuo Therapeutics, Inc. (f/k/a Cytomedix, Inc.) and its affiliates.
The filing was assigned docket number 68 and is described on the court’s official docket as follows:
[SEALED] Motion to Authorize // [SEALED] Debtor’s Motion for Entry of an Order Authorizing and Approving Key Employee Retention Plan Filed by Nuo Therapeutics, Inc.. Hearing scheduled for 2/22/2016 at 09:30 AM at US Bankruptcy Court, 824 Market St., 5th Fl., Courtroom #4, Wilmington, Delaware. Objections due by 2/16/2016. (Attachments: # (1) Notice) (Newman, Stacy)
Nuo Therapeutics, Inc. (f/k/a Cytomedix, Inc.) filed for bankruptcy protection, or had an involuntary bankruptcy petition filed against it, on January 26, 2016. The bankruptcy case is pending before the United States Bankruptcy Court for the District of Delaware. The case number for the lead bankruptcy case is 16-10192. The bankruptcy case is currently assigned to United States Bankruptcy Judge Mary Walrath. The law firm of Dentons US LLP is acting as lead bankruptcy counsel to Nuo Therapeutics, Inc. (f/k/a Cytomedix, Inc.) in the bankruptcy case.